Loading company…
Symeres is a Nijmegen-based CRO and CDMO offering small molecule drug discovery and development services.
Founded in 1987 in Nijmegen, Netherlands, Symeres provides integrated drug development as a contract research organization (CRO) and a contract development and manufacturing organization (CDMO). Services cover small molecule work from discovery through IND application, including hit generation, lead optimization and synthetic chemistry, for biotechnology firms and global pharmaceutical companies in Europe and North America. Its flagship is SymeGold, a compound library and screening service. Keensight Capital acquired a majority stake in May 2021 from Gilde Healthcare Partners and Pension Fund for General Practitioners. Eelco Ebbers is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in